CRBP vs. BMEA, MRSN, PEPG, MREO, TRDA, LXRX, AMRN, RVNC, ESPR, and TBPH
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Biomea Fusion (BMEA), Mersana Therapeutics (MRSN), PepGen (PEPG), Mereo BioPharma Group (MREO), Entrada Therapeutics (TRDA), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Corbus Pharmaceuticals' return on equity of -69.88% beat Biomea Fusion's return on equity.
96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Corbus Pharmaceuticals has higher revenue and earnings than Biomea Fusion. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biomea Fusion had 8 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 10 mentions for Biomea Fusion and 2 mentions for Corbus Pharmaceuticals. Biomea Fusion's average media sentiment score of 0.34 beat Corbus Pharmaceuticals' score of 0.16 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.
Corbus Pharmaceuticals received 397 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 66.61% of users gave Corbus Pharmaceuticals an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Biomea Fusion currently has a consensus target price of $53.25, suggesting a potential upside of 343.75%. Corbus Pharmaceuticals has a consensus target price of $52.00, suggesting a potential upside of 30.75%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Corbus Pharmaceuticals.
Biomea Fusion has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500.
Summary
Biomea Fusion beats Corbus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
